Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality

被引:26
|
作者
Hernandez-Torres, Alicia
Garcia-Vazquez, Elisa [1 ]
Gomez, Joaquin [1 ]
Canteras, Manuel [2 ]
Ruiz, Joaquin
Yaguee, Genoveva
机构
[1] Univ Murcia, Dept Internal Med, Fac Med, Murcia, Spain
[2] Univ Murcia, Dept Biostat, Fac Med, Murcia, Spain
来源
MEDICINA CLINICA | 2012年 / 138卷 / 15期
关键词
Acinetobacter baumannii; Multidrug resistant; Infection; Mortality; Treatment; NOSOCOMIAL INFECTIONS; CLINICAL-FEATURES; COLISTIN; BACTEREMIA; RIFAMPICIN; EPIDEMIOLOGY; COMBINATION; TIGECYCLINE; MONOTHERAPY; IMIPENEM;
D O I
10.1016/j.medcli.2011.06.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: To analyse factors related to mortality and influence of antibiotic treatment on outcome in patients with nosocomial infection due to multidrug and carbapenem-resistant Acinetobacter baumannii (MDR-C AB). Patients and methods: Observational and prospective study of a cohort of adult patients with MDR-C AB infection. Data collection from clinical records was done according to a standard protocol (January 2007 through June 2008). Patients with MDR-C AB infection were identified by review of results of microbiology cultures from the hospital microbiology laboratory. Epidemiological and clinical variables and predictors of mortality were analysed. Results: 24 out of 101 cases were considered colonizations and 77 infections (27 bacteraemia); global mortality in infected patients was 49% (18 cases with bacteraemia and 20 with no bacteraemia). In the multivariate analysis, including the 77 cases of infection, the prognosis factors associated with mortality were age (OR 1.09; 95% Cl 1.02-1.2), McCabe 1 (OR 33.98; 95% Cl 4.33-266.85), bacteraemia (OR 9.89; 95% Cl 1.13-86.13), inadequate empiric treatment (OR 16.7; 95% Cl 2.15-129.79), and inadequate definitive treatment (OR 26.29; 95% Cl 1.45-478.19). In the multivariate analysis including the 57 cases of infection with adequate definitive treatment, the prognosis factors associated with mortality were McCabe 1 (OR 24.08:95% Cl 3.67-157.96) and monotherapy versus combined treatment (OR 7.11; 95% Cl 1.63-30.99). Conclusions: Our cohort of patients with MDR-C AB infection is characterised by a very high mortality (49%); the severity of patients and inadequate treatment or monotherapy are statistically associated with mortality. 2011 (C) Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:650 / 655
页数:6
相关论文
共 50 条
  • [1] Risk Factors for Development and Mortality of Bloodstream Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
    Li, Liubing
    Chen, Dubo
    Liu, Pingjuan
    Dai, Luqi
    Tang, Zhaoxia
    Yi, Siting
    Ye, Mengmin
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 5699 - 5706
  • [2] Treating carbapenem-resistant Acinetobacter baumannii infections
    Giannella, Maddalena
    Viale, Pierluigi
    LANCET INFECTIOUS DISEASES, 2023, 23 (09): : 994 - 995
  • [3] Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia
    Liu, Chang-Pan
    Shih, Shou-Chuan
    Wang, Nai-Yu
    Wu, Alice Y.
    Sun, Fang-Ju
    Chow, Shan-Fan
    Chen, Te-Li
    Yan, Tsong-Rong
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2016, 49 (06) : 934 - 940
  • [4] Incidence of infections caused by carbapenem-resistant Acinetobacter baumannii
    Rossi, Iara
    Royer, Sabrina
    Ferreira, Melina Lorraine
    Campos, Paola Amaral
    Fuga, Bruna
    Melo, Gabriel Nogueira
    Machado, Luiz Gustavo
    Resende, Daiane Silva
    Batistao, Deivid
    Urzedo, Jane Eire
    Gontijo-Filho, Paulo P.
    Ribas, Rosineide Marques
    AMERICAN JOURNAL OF INFECTION CONTROL, 2019, 47 (12) : 1431 - 1435
  • [5] Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections
    Iovleva, Alina
    Fowler Jr, Vance G.
    Doi, Yohei
    DRUGS, 2025, 85 (01) : 21 - 40
  • [6] Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii
    Zhang, Siqin
    Di, Lingfang
    Qi, Yan
    Qian, Xiang
    Wang, Siwei
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [7] Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia
    Zheng, Yu-long
    Wan, Yu-feng
    Zhou, Li-yang
    Ye, Mao-lin
    Liu, Shu
    Xu, Chuan-qin
    He, Yuan-qiang
    Chen, Jian-hui
    AMERICAN JOURNAL OF INFECTION CONTROL, 2013, 41 (07) : E59 - E63
  • [8] Gut colonization by multidrug-resistant and carbapenem-resistant Acinetobacter baumannii in neonates
    Roy, S.
    Viswanathan, R.
    Singh, A.
    Das, P.
    Basu, S.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (12) : 1495 - 1500
  • [9] Mortality Attributable to Carbapenem-Resistant Nosocomial Acinetobacter baumannii Infections in a Turkish University Hospital
    Aydemir, Hande
    Celebi, Guven
    Piskin, Nihal
    Oztoprak, Nefise
    Keskin, Aysegul Seremet
    Aktas, Elif
    Sumbuloglu, Vildan
    Akduman, Deniz
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2012, 65 (01) : 66 - 71
  • [10] Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation
    Reddy, P.
    Zembower, T. R.
    Ison, M. G.
    Baker, T. A.
    Stosor, V.
    TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (01) : 87 - 93